Valuation: Insmed Incorporated

Market Cap 22.7B 19.92B 18.55B 17.06B 31.99B 2,169B 32.53B 220B 86.15B 1,076B 85.22B 83.38B 3,716B P/E 2026 *
-41x
P/E 2027 * 208x
Enterprise Value 22.14B 19.43B 18.09B 16.64B 31.19B 2,115B 31.73B 215B 84.01B 1,049B 83.11B 81.31B 3,624B EV / Sales 2026 *
13x
EV / Sales 2027 * 7.82x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day+0.41%
1 week-2.85%
Current month-1.03%
1 month+0.74%
3 months-21.80%
6 months-32.31%
Current year-39.37%
1 week 103.18
Extreme 103.18
109.99
1 month 103.08
Extreme 103.08
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.94
Extreme 20.94
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
+0.48%-2.85%+3.71%+394.24% 22.7B
-2.25%+1.55%+50.84%+70.04% 56.19B
-1.32%-0.97%+38.41%+77.52% 54.83B
+1.17%-0.42%-18.48%-14.41% 23.04B
-0.21%+0.84%+22.48%-7.92% 20.23B
0.00%+3.00%+27.41%-29.52% 17.83B
-0.97%+0.89%+37.28%+539.62% 15.65B
-6.69%-5.11%+166.00%+304.89% 15.24B
+1.23%+0.93%+27.60%+185.34% 14.03B
-2.52%-1.71%+82.70%+161.52% 12.71B
Average -1.12%-0.18%+43.79%+168.13% 25.24B
Weighted average by Cap. -1.19%+0.31%+40.07%+134.14%

Financials

2026 *2027 *
Net sales 1.7B 1.49B 1.39B 1.28B 2.4B 162B 2.44B 16.49B 6.45B 80.59B 6.39B 6.25B 278B 2.78B 2.44B 2.27B 2.09B 3.91B 265B 3.98B 26.92B 10.54B 132B 10.42B 10.2B 454B
Net income -561M -493M -459M -422M -791M -53.63B -804M -5.44B -2.13B -26.59B -2.11B -2.06B -91.88B 71.64M 62.87M 58.54M 53.85M 101M 6.84B 103M 695M 272M 3.39B 269M 263M 11.73B
Net Debt -563M -494M -460M -423M -793M -53.79B -807M -5.46B -2.14B -26.68B -2.11B -2.07B -92.17B -979M -859M -800M -736M -1.38B -93.49B -1.4B -9.49B -3.71B -46.36B -3.67B -3.59B -160B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-28 US$105.61 +0.84% 734,532
26-07-27 US$104.73 -2.05% 1,899,713
26-07-24 US$106.92 -0.46% 1,908,298
26-07-23 US$107.41 +0.72% 1,752,962
26-07-22 US$106.64 -1.82% 1,771,277
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
104.73USD
Average target price
196.18USD
Spread / Average Target
+87.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock